Bristol-Myers Squibb Company - Asset Resilience Ratio
Bristol-Myers Squibb Company (BMY) has an Asset Resilience Ratio of 1.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Bristol-Myers Squibb Company's Asset Resilience Ratio has changed over time. Check Bristol-Myers Squibb Company strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Bristol-Myers Squibb Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BMY stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $912.00 Million | 1.05% |
| Total Liquid Assets | $912.00 Million | 1.05% |
Asset Resilience Insights
- Limited Liquidity: Bristol-Myers Squibb Company maintains only 1.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bristol-Myers Squibb Company Industry Peers by Asset Resilience Ratio
Compare Bristol-Myers Squibb Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.29% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for Bristol-Myers Squibb Company (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Bristol-Myers Squibb Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.85% | $10.67 Billion | $90.04 Billion | +0.13pp |
| 2024-12-31 | 11.73% | $10.86 Billion | $92.60 Billion | -1.18pp |
| 2023-12-31 | 12.90% | $12.28 Billion | $95.16 Billion | +3.35pp |
| 2022-12-31 | 9.56% | $9.25 Billion | $96.82 Billion | -6.20pp |
| 2021-12-31 | 15.75% | $17.22 Billion | $109.31 Billion | +1.87pp |
| 2020-12-31 | 13.88% | $16.45 Billion | $118.48 Billion | +2.04pp |
| 2019-12-31 | 11.85% | $15.39 Billion | $129.94 Billion | -13.19pp |
| 2018-12-31 | 25.04% | $8.76 Billion | $34.99 Billion | +4.73pp |
| 2017-12-31 | 20.30% | $6.81 Billion | $33.55 Billion | +1.46pp |
| 2016-12-31 | 18.84% | $6.35 Billion | $33.71 Billion | +12.90pp |
| 2015-12-31 | 5.94% | $1.89 Billion | $31.75 Billion | +0.41pp |
| 2014-12-31 | 5.52% | $1.86 Billion | $33.75 Billion | +3.09pp |
| 2013-12-31 | 2.43% | $939.00 Million | $38.59 Billion | -0.83pp |
| 2012-12-31 | 3.27% | $1.17 Billion | $35.90 Billion | -5.70pp |
| 2011-12-31 | 8.97% | $2.96 Billion | $32.97 Billion | +1.67pp |
| 2010-12-31 | 7.30% | $2.27 Billion | $31.08 Billion | +4.62pp |
| 2009-12-31 | 2.68% | $831.00 Million | $31.01 Billion | +1.70pp |
| 2008-12-31 | 0.98% | $289.00 Million | $29.49 Billion | -0.64pp |
| 2007-12-31 | 1.62% | $424.00 Million | $26.17 Billion | -6.18pp |
| 2006-12-31 | 7.80% | $2.00 Billion | $25.57 Billion | -1.97pp |
| 2005-12-31 | 9.77% | $2.75 Billion | $28.14 Billion | -2.70pp |
| 2004-12-31 | 12.47% | $3.79 Billion | $30.43 Billion | +1.49pp |
| 2003-12-31 | 10.98% | $3.01 Billion | $27.45 Billion | +4.49pp |
| 2002-12-31 | 6.48% | $1.62 Billion | $25.02 Billion | +5.91pp |
| 2001-12-31 | 0.57% | $154.00 Million | $27.06 Billion | -0.59pp |
| 2000-12-31 | 1.15% | $203.00 Million | $17.58 Billion | -0.23pp |
| 1999-12-31 | 1.38% | $237.00 Million | $17.11 Billion | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for… Read more